183720-28-7

Basic information

• Product Name: (+/-)-BMS 204352
• Synonyms: (+/-)-BMS 204352;2H-INDOL-2-ONE, 3-(5-CHLORO-2-METHOXYPHENYL)-3-FLUORO-1,3-DIHYDRO-6-(TRIFLUOROMETHYL)-;3-(5-CHLORO-2-METHOXY-PHENYL)-3-FLUORO-6-TRIFLUOROMETHYL-1,3-DIHYDRO-INDOL-2-ONE;3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one
• CAS NO: 183720-28-7
• Molecular Formula: C₁₆H₁₀ClF₄NO₂
• Molecular Weight: 359.7
• Mol File: 183720-28-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 436.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.50±0.1 g/cm3(Predicted)
• PKA: 10.43±0.40(Predicted)
• CAS DataBase Reference: (+/-)-BMS 204352(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-BMS 204352(183720-28-7)
• EPA Substance Registry System: (+/-)-BMS 204352(183720-28-7)

Safety Data

• Hazardous Substances Data: 183720-28-7(Hazardous Substances Data)

Usage

General Description

(+/-)-BMS 204352, also known as BMS-204352, is a chemical compound that acts as a potent and selective inhibitor of human 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme is responsible for the conversion of inactive cortisone into active cortisol in the liver and adipose tissue. By inhibiting this enzyme, (+/-)-BMS 204352 can potentially reduce the levels of cortisol in the body, which could be beneficial in treating conditions such as metabolic syndrome, diabetes, and obesity. Research on this compound has shown promising results in animal models, suggesting its potential as a therapeutic agent for various cortisol-related disorders. However, further studies are needed to fully understand its safety and efficacy in humans.

Upstream product

• 206194-00-5 5-chloro-α-fluoro-2-methoxy-α-[2-nitro-4-(trifluoromethyl)-phenyl]benzeneacetic acid,methyl ester 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 
• 26939-01-5 5-chloro-2-methoxyphenylacetic acid,methyl ester 
• 183720-52-7 methyl 2-(5-chloro-2-methoxyphenyl)-2-(2-nitro-4-(trifluoromethyl)phenyl)acetate 
• 635305-45-2 2-(5-chloro-2-(methoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 89694-48-4 5-chloro-2-methoxyphenyl boronic acid 

Downstream Products

• 187523-36-0 (-)-BMS-204352 
• 187523-35-9 (S)-(+)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one 
• 607740-72-7 3-(5-chloro-2-methoxy-phenyl)-3-fluoro-1-methylsulfanylmethyl-6-trifluoromethyl-1,3-dihydro-indol-2-one 

Relevant articles and documents

Novel synthesis method for Flindokalner raceme

The invention discloses a novel synthesis method for a Flindokalner raceme. The method comprises the steps: subjecting 3-fluoro-3-(2,2,2-trifluoro-1,1-dihydroxyethyl)-6(trifluoromethyl)2H-indol-2-one, which serves as a raw material, to a bromation reactio

PREPARATION OF 3-FLUORO OXINDOLE DERIVATIVES

The present invention relates to novel itermediates of formula (1) wherein the wavy bond ( SIMILAR SIMILAR ) represents the racemate, the (R)-enantiomer or the (S)-enantiomer; and R is hydrogen, a carboxyl-protecting group or a cation of an addition salt;

Methods for treating hyperactive gastric motility

This invention provides methods and pharmaceutical compositions for treating, inhibiting or preventing hyperactive gastric motility in a mammal utilizing agonists of KCNQ potassium channels, including KCNQ2, KCNQ3, KCNQ4 and KCNQ5 potassium channels, alone or in combination. The hyperactive gastric motility may be associated with maladies including, colitis, irritable bowel syndrome and Crohn's disease. Compounds useful in these methods include the 1,2,4-triamino-benzene derivatives described in U.S. Pat. No. 5,384,330 (Dieter et al.) and the substituted 3-phenyl oxindole compounds described in U.S. Pat. No. 5,565,483 (Hewawasam et al.). Among the preferred compounds of this invention is N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also referred to as retigabine.